Tazemetostat may increase the risk of secondary malignancies and fetal harm, requiring specific precautions.

Warnings and Precautions for Tazemetostat

Tazemetostat carries a risk of developing secondary malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and other hematologic cancers. It should not be used during pregnancy as it may cause fetal harm, and patients should use effective non-hormonal contraception during treatment and for six months after the last dose. The drug also poses risks of hematologic issues, and long-term monitoring is required for secondary malignancies.